M&A M&A
Dr Reddy's Labs to acquire anti-dizziness drug Stugeron from Johnson & Johnson for $51-M
Source Business Standard (opens in a new tab)BSE Announcement (opens in a new tab)
Hyderabad-based publicly listed Dr. Reddy's Laboratories is to acquire the Stugeron brand across 18 markets in the Asia-Pacific (APAC) and Europe, Middle East, and Africa (EMEA) regions, including India and Vietnam, from Johnson & Johnson (via Janssen Pharmaceutica NV) for USD 50.5 million.Stugeron is mainly used to help stop dizziness, nausea, and vomiting caused by motion sickness and also to address balance disorders and inner ear problems, like vertigo. Stugeron contains cinnarizine, an antihistamine indicated for the treatment of vestibular disturbances and vertigo.